EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Nkarta's enterprise value is $128.26 Mil.
Nkarta's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil. Therefore, Nkarta's EV-to-Revenue for today is .
The historical rank and industry rank for Nkarta's EV-to-Revenue or its related term are showing as below:
During the past 6 years, the highest EV-to-Revenue of Nkarta was 5144.86. The lowest was -152.76. And the median was 758.03.
NKTX's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 8.1 * Ranked among companies with meaningful EV-to-Revenue only.
As of today (2024-06-01), Nkarta's stock price is $6.79.
Nkarta's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00. Therefore, Nkarta's PS Ratio for today is .
Nkarta EV-to-Revenue Historical Data
The historical data trend for Nkarta's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Nkarta's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nkarta's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nkarta's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Nkarta's EV-to-Revenue falls into.
Nkarta's current Enterprise Value is $128.26 Mil.
Nkarta's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nkarta's share price for today is $6.79.
Nkarta's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nkarta EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Nkarta's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Nkarta Inc is a biopharmaceutical company engaged in developing engineered natural killer (NK) cells to treat cancer. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of tumor targets, and improve persistence for sustained activity in the body for the treatment of cancer. The Company's operations are based in South San Francisco, California.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NKTX has been successfully added to your 